The Health and Environmental Sciences Institute (HESI) is a non-profit institution whose mission is to collaboratively identify and help to resolve global health and environmental challenges through the engagement of scientists from academia, government, industry, NGOs, and other strategic partners.
HESI values the contributions and expertise of each of our 1,000+ partner scientists from around the globe. Check out some of our most exciting collaborations and highlights below.
In honor of its 50th anniversary, Critical Reviews in Toxicology published a special editorial that lists two RISK21 Committee publications among the journal’s top 25 most read papers. Click here to read the editorial.
“A 21st Century Roadmap for Human Health Risk Assessment”
(Pastoor et al. 2014;44 Suppl 3:1–5)
“Risk Assessment in the 21st Century: Roadmap and Matrix”
(Embry et al. 2014;44 Suppl 3:6–16)
The Botanical Safety Consortium (BSC) was officially convened in November 2019 as the result of a Memorandum of Understanding (MOU) between the US Food and Drug Administration (FDA), the National Institute of Health’s National Institute of Environmental Health Sciences (NIEHS), and HESI, and through a federal funding award to HESI from those agencies. The mission of the BSC is to provide a forum for global scientists from government, academia, consumer health groups, industry, and non-profit organizations to work collaboratively to generate a sound scientific basis for integrating existing safety data and the latest toxicology tools to evaluate safety in botanical dietary supplements.
In 2019, the HESI Cardiac Safety Committee was awarded a U01 grant from the US Food and Drug Administration (FDA) on the “Evaluation of Integrated Human-Relevant Approaches to Identify Drug-Induced Cardiovascular Liabilities.” This grant supports HESI’s role in awarding and managing novel, in vitro experimental studies to develop targeted mechanistic data to inform drug safety assessment for key cardiac “failure modes.” HESI Cardiac Safety Committee members have identified six main failure modes, or CV liabilities contributing to drug attrition.
In June 2020, HESI launched a novel collaboration with clinical and research colleagues around the world to advance more efficient and accessible SARS-CoV-2 testing methods. The PROPAGATE Network, a voluntary global network of lab scientists in these countries, will assess the reproducibility and utility of an extraction-less PCR testing method developed by participating scientists at the University of Washington and University of Vermont. This method has the potential to be used as a screening test that requires fewer experimental resources, lower costs, and less time than traditional PCR analysis.
RT-qPCR is used world-wide to ...
This commentary details the structure, goals, and strategies of the BSC and insights regarding our objectives, namely the selection and prioritization of botanicals based on putative toxicological properties.
The HESI Genetic Toxicology Technical Committee (GTTC) applies their systematic and flexible approach for assessing the risk of genetic damage due to exposure to chemical substances to etoposide, a drug used in certain types of cancer treatments, as a representative pharmaceutical ...
Human health risks from chronic exposures to environmental chemicals are typically estimated from potential human exposure estimates and dose-response data obtained from repeated-dose animal toxicity studies. Various criteria are available for selecting the top (highest) dose used in ...